| Literature DB >> 31856176 |
Wogba Kamara1, Kathryn L Zoerhoff2, Emily H Toubali3, Mary H Hodges4, Donal Bisanzio2, Dhuly Chowdhury5, Mustapha Sonnie4, Edward Magbity6, Mohamed Samai7, Abdulai Conteh8, Florence Macarthy8, Margaret Baker2, Joseph B Koroma9.
Abstract
BACKGROUND: Preventive chemotherapy was administered to 3.2 million Sierra Leoneans in 13 health districts for lymphatic filariasis, onchocerciasis, and soil transmitted helminthes from October 2008 to February 2009. This paper aims to report the findings of a coverage survey conducted in 2009, compare the coverage survey findings with two reported rates for lymphatic filariasis coverage obtained using pre-mass drug administration (MDA) registration and national census projections, and use the comparison to understand the best source of population estimates in calculating coverage for NTD programming in Sierra Leone. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2019 PMID: 31856176 PMCID: PMC6922463 DOI: 10.1371/journal.pone.0224422
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
MDA coverage calculated using survey data, census population, and pre-MDA population and their comparison.
| Survey (95% CI) | Reported–Census denominator | Reported–pre-MDA registration | Difference Survey and Census in percentage points: point estimate (95% CI) | Difference Survey and pre-MDA in percentage points: point estimate (95% CI) | |
|---|---|---|---|---|---|
| IVM coverage | 66.9% (61.8, 71.7) | 69.5% | 70.1% | -2.6 (-7.7, 2.2) | -3.2 (-8.3, 1.6) |
| ALB coverage | 66.6% (61.5, 71.4) | 69.5% | 70.1% | -2.9 (-8.1, 1.9) | -3.5 (-8.6, 1.3) |
| IVM Kendall’s W | - | 0.56 | 0.64 | - | - |
| ALB Kendall’s W | - | 0.59 | 0.68 | - | - |
The table shows the difference and agreement among the methods (Kendall’s W).
Fig 1Coverage calculated using reported treatment coverage–with both pre-MDA registration and census denominators–and post MDA coverage survey.
The panels show IVM (A) and ALB (C) coverage calculated using reported coverage (with either census or pre-MDA registration as the denominator) and survey methods. A significantly statistical difference between surveyed and reported coverage rates is shown with an *. Panels B and D use boxplots to show the distribution of district level differences between surveyed coverage and reported coverage rates.
Fig 2Survey coverage of IVM and ALB at district level and districts with statistically high and low surveyed coverage.
The image shows surveyed coverage calculated for IVM (Panel A) and for ALB (Panel B). The figure also includes a map (Panel C) showing significant clusters of districts where people had significant lower and higher probability to take MDA drugs (IVM and ALB, one map is shown because drug models had same results) compared with the rest of districts. This map is the result of the random spatial effect variable of the logistic regression.
Surveyed coverage % (95% confidence interval) by age group, sex at country level.
| Age group | % IVM | % ALB |
|---|---|---|
| 5<15 (Ref. age group) | 74.5 (70.3–78.3) | 73.6 (69.3–77.6) |
| 15<30 | 64.2 (59.3–68.8) | 63.6 (58.6–68.2) |
| ≥30 | 74.7 (70.9–78.2) | 73.5 (69.4–77.3) |
| Male (Ref. = Female) | 65.0 (61.4–68.4) | 64.0 (60.3–67.6) |
| Female | 58.6 (54.7–62.4) | 58.1 (54.1–62.0) |
| No pregnant females (Ref. = Male) | 63.1 (58.5–69.8) | 64.1 (59.2–68.7) |
*p<0.05
**p<0.01, p-value from GLMM logistic regressions (model results are showed in Table 3).
Results from logistic regression GLMM.
| IVM model | ALB model | |
|---|---|---|
| Intercept | 1.81 (1.15, 2.84) | 1.83 (1.191, 2.82) |
| Sex: | ||
| Female (Ref) | 1.0 | 1.0 |
| Male | 1.34 (1.22, 1.47) | 1.30 (1.18, 1.43) |
| Age groups: | ||
| 5<15 years (Ref) | 1.0 | 1.0 |
| 15<30 years | 0.71 (0.63, 0.80) | 0.70 (0.62, 0.79) |
| ≥30 years | 1.26 (1.12, 1.42) | 1.18 (1.06, 1.33) |
| District |
* = p<0.05
** = p<0.01
aspatial random effect showed in Fig 2C